Compare Medpace Holdings Inc (MEDP) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs SiTime Corporation — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while SiTime Corporation trades at $612.37 (market cap $19.42B). The key difference: SiTime Corporation is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and SiTime Corporation for 18 Days on average.
| MEDP | SITM | |
|---|---|---|
Market Cap | $16.82B | $19.42B |
Volume | 223,093 | 360,307 |
Sector | Health | Technology |
52-Week High | $630.19 | $901.60 |
52-Week Low | $393.42 | $252.76 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $16.44B | $18.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SITM trades at $612.37, down 7.94% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with a 126.5% revenue surge to $157.43M and achieving its first GAAP profit. Analyst consensus is unanimously bullish with a $751.43 price target, citing AI-driven growth and market leadership in MEMS timing solutions.
The outlook is positive, driven by AI infrastructure demand and operational leverage, but risks include high valuation multiples, negative 2025 net income, and insider selling. The stock offers significant upside potential if growth continues, though execution and market volatility pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
